Weidun Xie , Xingjian Chen , Lei Huang , Zetian Zheng , Yuchen Wang , Ruoxuan Zhang , Xiao Zhang , Zhichao Liu , Chengbin Peng , Monika Gullerova , Ka-chun Wong
{"title":"ddensity:使用预训练的深度学习模型嵌入来处理不平衡的药物-药物相互作用风险水平","authors":"Weidun Xie , Xingjian Chen , Lei Huang , Zetian Zheng , Yuchen Wang , Ruoxuan Zhang , Xiao Zhang , Zhichao Liu , Chengbin Peng , Monika Gullerova , Ka-chun Wong","doi":"10.1016/j.artmed.2025.103202","DOIUrl":null,"url":null,"abstract":"<div><div>Imbalanced datasets have been a persistent challenge in bioinformatics, particularly in the context of drug-drug interaction (DDI) risk level datasets. Such imbalance can lead to biased models that perform poorly on underrepresented classes. To address this issue, one strategy is to construct a balanced dataset, while another involves employing more advanced features and models. In this study, we introduce a novel approach called DDintensity, which leverages pre-trained deep learning models as embedding generators combined with LSTM-attention models to address the imbalance in DDI risk level datasets. We tested embeddings from various domains, including images, graphs, and textual corpus. Among these, embeddings generated by BioGPT achieved the highest performance, with an Area Under the Curve (AUC) of 0.97 and an Area Under the Precision-Recall curve (AUPR) of 0.92. Our model was trained on the DDinter and further validated using the MecDDI dataset. Additionally, case studies on chemotherapeutic drugs, DB00398 (Sorafenib) and DB01204 (Mitoxantrone) used in oncology, were conducted to demonstrate the specificity and effectiveness of the this methods. Our approach demonstrates high scalability across DDI modalities, as well as the discovery of novel interactions. In summary, we introduce DDIntensity as a solution for imbalanced datasets in bioinformatics with pre-trained deep-learning embeddings.</div></div>","PeriodicalId":55458,"journal":{"name":"Artificial Intelligence in Medicine","volume":"168 ","pages":"Article 103202"},"PeriodicalIF":6.2000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"DDintensity: Addressing imbalanced drug-drug interaction risk levels using pre-trained deep learning model embeddings\",\"authors\":\"Weidun Xie , Xingjian Chen , Lei Huang , Zetian Zheng , Yuchen Wang , Ruoxuan Zhang , Xiao Zhang , Zhichao Liu , Chengbin Peng , Monika Gullerova , Ka-chun Wong\",\"doi\":\"10.1016/j.artmed.2025.103202\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Imbalanced datasets have been a persistent challenge in bioinformatics, particularly in the context of drug-drug interaction (DDI) risk level datasets. Such imbalance can lead to biased models that perform poorly on underrepresented classes. To address this issue, one strategy is to construct a balanced dataset, while another involves employing more advanced features and models. In this study, we introduce a novel approach called DDintensity, which leverages pre-trained deep learning models as embedding generators combined with LSTM-attention models to address the imbalance in DDI risk level datasets. We tested embeddings from various domains, including images, graphs, and textual corpus. Among these, embeddings generated by BioGPT achieved the highest performance, with an Area Under the Curve (AUC) of 0.97 and an Area Under the Precision-Recall curve (AUPR) of 0.92. Our model was trained on the DDinter and further validated using the MecDDI dataset. Additionally, case studies on chemotherapeutic drugs, DB00398 (Sorafenib) and DB01204 (Mitoxantrone) used in oncology, were conducted to demonstrate the specificity and effectiveness of the this methods. Our approach demonstrates high scalability across DDI modalities, as well as the discovery of novel interactions. In summary, we introduce DDIntensity as a solution for imbalanced datasets in bioinformatics with pre-trained deep-learning embeddings.</div></div>\",\"PeriodicalId\":55458,\"journal\":{\"name\":\"Artificial Intelligence in Medicine\",\"volume\":\"168 \",\"pages\":\"Article 103202\"},\"PeriodicalIF\":6.2000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Artificial Intelligence in Medicine\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S093336572500137X\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"COMPUTER SCIENCE, ARTIFICIAL INTELLIGENCE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Artificial Intelligence in Medicine","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S093336572500137X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"COMPUTER SCIENCE, ARTIFICIAL INTELLIGENCE","Score":null,"Total":0}
DDintensity: Addressing imbalanced drug-drug interaction risk levels using pre-trained deep learning model embeddings
Imbalanced datasets have been a persistent challenge in bioinformatics, particularly in the context of drug-drug interaction (DDI) risk level datasets. Such imbalance can lead to biased models that perform poorly on underrepresented classes. To address this issue, one strategy is to construct a balanced dataset, while another involves employing more advanced features and models. In this study, we introduce a novel approach called DDintensity, which leverages pre-trained deep learning models as embedding generators combined with LSTM-attention models to address the imbalance in DDI risk level datasets. We tested embeddings from various domains, including images, graphs, and textual corpus. Among these, embeddings generated by BioGPT achieved the highest performance, with an Area Under the Curve (AUC) of 0.97 and an Area Under the Precision-Recall curve (AUPR) of 0.92. Our model was trained on the DDinter and further validated using the MecDDI dataset. Additionally, case studies on chemotherapeutic drugs, DB00398 (Sorafenib) and DB01204 (Mitoxantrone) used in oncology, were conducted to demonstrate the specificity and effectiveness of the this methods. Our approach demonstrates high scalability across DDI modalities, as well as the discovery of novel interactions. In summary, we introduce DDIntensity as a solution for imbalanced datasets in bioinformatics with pre-trained deep-learning embeddings.
期刊介绍:
Artificial Intelligence in Medicine publishes original articles from a wide variety of interdisciplinary perspectives concerning the theory and practice of artificial intelligence (AI) in medicine, medically-oriented human biology, and health care.
Artificial intelligence in medicine may be characterized as the scientific discipline pertaining to research studies, projects, and applications that aim at supporting decision-based medical tasks through knowledge- and/or data-intensive computer-based solutions that ultimately support and improve the performance of a human care provider.